Página 1 desde 118 resultados
FIELD OF INVENTION
A product for use in the treatment of obesity, the metabolic syndrome, type 2 diabetes, cardiovascular diseases, dementia, alzheimers disease and inflammatory bowel disease comprising at least one isolated bacterial strain from the species Prevotellaceae, herein the strain is
BACKGROUND OF THE INVENTION
Field of the Invention
This invention relates to algal biochemistry, and more specifically, to algal compositions and methods of utilization.
SUMMARY OF THE INVENTION
Provided herein are exemplary products for mammalian consumption selected from any of a composition
CROSS REFERENCE TO RELATED APPLICATIONS
This application is a National Stage of International Application No. PCT/JP2012/081744 filed Dec. 7, 2012, claiming priority based on Japanese Patent Application No. 2011-268561 filed Dec. 8, 2011, the contents of all of which are incorporated herein by
RELATED APPLICATIONS
The instant application is the U.S. National Phase under 35 U.S.C. .sctn.371 of International Application No. PCT/CN2009/073140 entitled COMPOUND WITH AGITATION EFFECT ON PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR .delta., AND PREPARATION METHOD AND USE THEREOF, filed Aug. 7,
TECHNICAL FIELD
The present invention relates to a nitrogen-containing bicyclic compound or a pharmacologically acceptable salt thereof and a pharmaceutical composition comprising it as active ingredient.
More specifically, the present invention relates to (1) a compound of formula (I)
##STR00002##
BACKGROUND OF THE INVENTION
The present invention relates to novel benzopyran ER-.beta. agonist compounds, pharmaceutical compositions thereof, and use of these compounds to treat a ER-.beta. mediated disease such as benign prostatic hypertrophy, obesity, dementia, hypertension, incontinence, colon
FIELD OF THE INVENTION
The present invention relates to a novel treatment of low total androgens accompanied by one or more symptoms classically attributed to male hypogonadism or low testosterone. The number of individuals over 65 years of age has increased more than 10-fold compared with the 1990s
FIELD OF THE INVENTION
The present invention relates to a novel treatment of low total androgens accompanied by one or more symptoms classically attributed to male hypogonadism or low testosterone. The number of individuals over 65 years of age has increased more than 10-fold compared with the 1990s
TECHNICAL FIELD
The present invention relates to a piperidine derivative.
More specifically, the present invention relates to (1) a piperidine derivative of formula (I)
##STR00002## (2) a method for the preparation thereof, (3) a composition comprising it as an active ingredient, (4) a compound of
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11.beta.-hydroxysteroid dehydrogenase type 1 (11.beta.-HSD1). The present invention also
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11.beta.-hydroxysteroid dehydrogenase type 1 (11.beta.-HSD1). The present invention also
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11.beta.-hydroxysteroid dehydrogenase type 1 (11.beta.-HSD1). The present invention also
TECHNICAL FIELD
This invention relates to 25-hydroxyvitamin D.sub.3 24-hydroxylase transgenic animals.
BACKGROUND ART
The transgenic animal carries a gene introduced to its own or progenitor's germ cell line in an early stage of development (usually, single cells).
Wagner et al. (1981, ProNAS, USA,
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain (4-phenyl-piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds that, inter alfa, inhibit 11.beta.-hydroxysteroid
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thi- ophen-3-yl]-methanone,